- Morgan Stanley downgraded ADC Therapeutics ( NYSE: ADCT ) to Equal Weight from Overweight in a research note issued on Friday.
- The investment bank lowered its price target to $11 from $17 on the commercial-stage biotechnology firm ADC Therapeutics ( ADCT ), citing Zynlonta penetration concerns.
- Stock is down 6% to trade at $6.16 on Friday.
- Seeking Alpha Quant Rating system assigns a Sell rating to ADCT, which sets the stock analysis stand apart from Wall Street's Strong Buy.
For further details see:
ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11